BIRMINGHAM, Ala., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Forager Capital Management (“Forager”), one of the largest shareholders of Quipt Home Medical Corp. (“Quipt”) (NASDAQ: QIPT; TSX: QIPT), with beneficial ownership of 9.7%, today announced it has submitted a proposal to acquire all outstanding shares of Quipt for $3.10 per share in cash (the “Acquisition Proposal”).
The Acquisition Proposal is not subject to any due diligence or financing conditions and is capable of being executed immediately. The offer represents a 120% premium to Quipt’s unaffected share price of $1.41 at close on May 19, 2025, the trading day prior to Forager’s prior proposal being made public.
In addition to reaffirming its commitment to the Acquisition Proposal, Forager is prepared to improve its offer if the Board engages in constructive discussions.
The Acquisition Proposal also includes a go-shop provision, allowing the Board to actively solicit superior offers following the execution of definitive agreements. If a higher bidder exists, they are welcome to step forward. Forager believes its Acquisition Proposal delivers immediate and certain value to all shareholders.
The full text of the Acquisition Proposal will be filed as an exhibit to an amended Schedule 13D.
Contact:
Johnny Wilhelm
Partner Forager
Capital Management, LLC
205-383-4763
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.63 |
| Daily Volume: | 151,813 |
| Market Cap: | US$114.250M |
August 12, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
